Abstract
Emicizumab, a bispecific humanised monoclonal antibody restoring to some extent the function of activated FVIII deficient in haemophilia A, represents a major therapeutic advance in the management of haemophilia A patients. No dosage adjustment is required, which leads to a major change for patients used to regular biological monitoring which is particularly burdensome in the case of substitution therapy. In some circumstances, such as before an invasive procedure or in case of bleeding, biological monitoring will be necessary and emicizumab's interference with haemostasis tests, particularly those based on an activated partial thromboplastin times (aPTT), must be known to best interpret the tests and to select the most appropriate methods to guide therapy. The normalisation of aPTT in patients treated with emicizumab is not sufficient to consider haemostasis as normalised. In the event of administration of FVIII to a patient receiving emicizumab, the determination of FVIII should use a chromogenic method using non-human reagents. Coagulation global tests have been proposed to evaluate the biological response when using bypassing agents in patients treated with emicizumab, but the usefulness must be confirmed. The French group ...Continue Reading
References
Dec 3, 2015·Blood·Naoki UchidaMidori Shima
May 26, 2016·The New England Journal of Medicine·Midori ShimaKeiji Nogami
Jul 12, 2017·The New England Journal of Medicine·Johannes OldenburgMidori Shima
Oct 19, 2017·Blood·Peter J LentingOlivier D Christophe
Feb 24, 2018·Haematologica·Yesim DargaudClaude Negrier
Jun 12, 2018·Journal of Thrombosis and Haemostasis : JTH·R HartmannF Scheiflinger
Aug 30, 2018·The New England Journal of Medicine·Johnny MahlanguRebecca Kruse-Jarres
Nov 16, 2018·Haemophilia : the Official Journal of the World Federation of Hemophilia·E Carlos Rodriguez-Merchan, Leonard A Valentino
Apr 21, 2019·The Lancet. Haematology·Steven W PipeVictor Jiménez-Yuste
May 8, 2019·Thrombosis and Haemostasis·Joanne I AdamkewiczIdo Paz-Priel
Jun 17, 2019·Thrombosis and Haemostasis·Jens MüllerMichael Spannagl
Jun 30, 2019·International Journal of Hematology·Koji YadaMidori Shima
Jul 6, 2019·Therapeutic Advances in Hematology·Hande KizilocakGuy Young
Jul 12, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Sophie SusenClaude Négrier
Nov 2, 2019·International Journal of Laboratory Hematology·Joanne I AdamkewiczIdo Paz-Priel
Dec 21, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·P Vincent JenkinsWill Lester
Apr 7, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Annette BowyerRhona Maclean
May 30, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Annette E BowyerStefan Tiefenbacher